Halia Therapeutics Reveals Promising Preclinical Obesity Data: HT-6184 and Semaglutide Combination Enhances Weight Loss and Preserves Lean Muscle Mass

LEHI, Utah, Sept. 23, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company advancing novel therapies for inflammation-related diseases, today announced promising preclinical results from their investigational compound HT-6184, combined with the…